CBUSNasdaqAgricultural ChemicalsUS GAAP · USD

Cibus, Inc.

Cibus, Inc. develops gene-edited plant traits using its proprietary RTDS platform, with a current focus on weed-management traits for rice and canola. The company also pursues partner-funded sustainable ingredients and other trait programs, monetizing its technology through collaboration agreements, licenses, and future royalties rather than selling finished farm products.

Kysy yhtiöstä
Liikevaihto3,6milj. USD
−14,6 %v/v
Liikevoitto (EBIT)−97,5milj. USD
+62,3 %v/v
EBIT-marginaali−2 680,1%
+3 382,7 %-yks.v/v
Nettotulos−127milj. USD
+49,4 %v/v
Vapaa kassavirta−51,2milj. USD
+13,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−400−300−200−1000100milj. USD2020: 24 milj. USD2020: EBIT −44 milj. USD20202021: 26 milj. USD2021: EBIT −29 milj. USD20212022: 0,16 milj. USD2022: EBIT −22 milj. USD20222023: 1,8 milj. USD2023: EBIT −319 milj. USD20232024: 4,3 milj. USD2024: EBIT −258 milj. USD20242025: 3,6 milj. USD2025: EBIT −98 milj. USD20253,6−98
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Cibus, Inc.

Liiketoiminta

Osuus liikevaihdosta
Gene editing platform0 %

Core RTDS technology used to edit elite germplasm with targeted trait changes.

Rice traits45 %

Herbicide tolerance and stacked trait lines for rice commercialization.

Canola and WOSR traits15 %

Trait development for canola and winter oilseed rape, including disease resistance work.

Soybean traits10 %

Soybean editing programs such as HT2 used to expand the platform and future partnerships.

Sustainable ingredients and biofragrance30 %

Partner-supported ingredient and fermentation-based product development programs.

Asiakkaat

Cibus sells primarily to seed companies, agricultural partners, and prospective commercial licensees that want trait-enabled germplasm rather than a finished consumer product. Its rice program is being advanced with prospective customers in rice-growing geographies, while sustainable ingredients and biofragrance work is partly funded by a consumer-packaged goods partner. Revenue today is driven by collaboration agreements, contract research, and development support rather than broad commercial product sales.

Seed companies and breeding partners

Buy trait access and edited germplasm to incorporate Cibus traits into commercial seed lines.

Agricultural collaboration partners

Fund contract research and development milestones for rice, canola, and other traits.

Consumer-packaged goods partner

Supports sustainable ingredients development and helps fund commercialization work.

Prospective rice commercial customers

Engage for rice herbicide tolerance traits in geographies where rice is cultivated globally.

Future licensees and royalty partners

Would commercialize products containing Cibus intellectual property and pay fees or royalties.

Strategia

Cibus is narrowing its focus to weed management in rice and partner-supported sustainable ingredients to preserve capital and improve execution. The company is pushing its RTDS platform through regulatory validation and field trials so it can move edited traits into customer germplasm and commercial launches. Cost reductions, facility rationalization, and workforce streamlining are intended to reduce cash burn and extend runway while the company advances toward initial commercialization.

Commercialize rice herbicide tolerance traitsLyhyt aikaväli

Rice is the clearest near-term path to revenue and customer adoption.

Convert RTDS validation into broader regulatory acceptanceKeskipitkä aikaväli

Lower regulatory barriers should shorten development cycles and expand addressable markets.

Preserve capital and reduce burnLyhyt aikaväli

The company remains loss-making and needs runway to reach commercialization milestones.

Monetize partner-funded sustainable ingredientsKeskipitkä aikaväli

This provides non-dilutive funding and diversifies the revenue base.

Maantiede

Cibus is headquartered in the United States and conducts development work across the U.S. and international agricultural markets. Recent regulatory validation in the United States, Ecuador, and the UK supports its commercialization path, while Latin America is becoming important for rice trait rollout through the Semillano collaboration. The company also references future expansion into the U.S. and broader global rice-growing regions, making regulatory frameworks a key geographic driver of timing and market access.

Riskit

Cibus remains an early-commercial biotech company with limited revenue, ongoing losses, and dependence on external funding and partner support. Its strategy is concentrated in rice and a few adjacent programs, so delays in regulation, customer adoption, or trait performance could materially affect execution and cash needs. The company also faces restructuring-related operational risk, litigation exposure, and the usual agricultural biotech risks around field trial outcomes, competitor innovation, and market acceptance.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Commercialization delay in rice traits1Restructuring execution risk4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Commercialization delay in rice traitsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Revenue depends on moving edited traits into customer germplasm and achieving regulatory clearance and adoption.

    KohdistuuLatin America launch timingU.S. expansionCustomer conversion
  2. Financing and liquidity riskVaikutus: Korkea

    The company has incurred losses since inception and expects continued losses before commercialization scales.

    KohdistuuCash on handFuture equity/debt accessCommercialization timing
  3. Regulatory riskVaikutus: Korkea

    Gene-edited crop commercialization depends on evolving rules in each market.

    KohdistuuUnited StatesEcuadorUKEU
  4. Restructuring execution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Workforce and facility reductions may reduce institutional knowledge and disrupt development.

    KohdistuuTalent retentionMoraleOperational continuity
  5. Litigation and contingent liability riskVaikutus: Keskitaso

    The company accrued a liability related to a Ninth Circuit decision and insurance proceeds repayment.

    Kohdistuu: Cash outflow and earnings impact

Kysy Clarifolta: Cibus, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for collaboration agreements

Revenue is driven by contract research, milestones, and license-related arrangements, which can be timing-sensitive.

Vaikutus: Quarterly revenue volatility

Goodwill impairment

The company recorded a large goodwill impairment, showing that asset values are highly sensitive to revised expectations.

Vaikutus: Non-cash operating loss volatility

Litigation liability accrual

A court-related repayment obligation required an estimated accrual.

Vaikutus: Balance sheet liability and earnings impact

Going concern and liquidity estimates

Management must assess whether cash and financing sources are sufficient to fund operations.

Vaikutus: Disclosure risk and investor perception of runway

Restructuring and lease exit accounting

Workforce reductions and facility rationalization can create severance, exit, and lease-related charges.

Vaikutus: Expense timing and cash usage

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Cibus Nordic Real Estate

CIBUS · Real Estate

Origin Agritech LTD

SEED · Agricultural Production-Crops

Bioceres Crop Solutions Corp.

BIOX · Agricultural Chemicals

Pyxus International, Inc.

PYYX · Wholesale-Farm Product Raw Materials

Terns Pharmaceuticals, Inc.

Pharmaceutical Preparations

Beam Therapeutics Inc.

BEAM · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026

Cibus, Inc. (CBUS) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo